GSK receives FDA approval of Blujepa for treatment of uncomplicated UTIs

GSK’s (GSK) Blujepa was approved by the FDA for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms with uncomplicated urinary tract infections caused by the following susceptible microorganisms, according to prescribing information posted to the agency’s website.